Reported Earnings • May 11
Third quarter 2026 earnings released: S$0.001 loss per share (vs S$0.002 loss in 3Q 2025) Third quarter 2026 results: S$0.001 loss per share (improved from S$0.002 loss in 3Q 2025). Revenue: S$1.59m (down 22% from 3Q 2025). Net loss: S$916.0k (loss narrowed 53% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 64% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 30
iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 0.440537 million. iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 0.440537 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,045,164
Price\Range: SGD 0.4215
Transaction Features: Subsequent Direct Listing Announcement • Apr 17
iX Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of SGD 0.440537 million. iX Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of SGD 0.440537 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,045,164
Price\Range: SGD 0.4215
Transaction Features: Subsequent Direct Listing New Risk • Apr 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Singaporean stocks, typically moving 21% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Earnings have declined by 7.8% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). New Risk • Mar 01
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 7.8% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (17% increase in shares outstanding). Reported Earnings • Feb 10
First half 2026 earnings released: S$0.002 loss per share (vs S$0.007 loss in 1H 2025) First half 2026 results: S$0.002 loss per share (improved from S$0.007 loss in 1H 2025). Revenue: S$3.18m (down 14% from 1H 2025). Net loss: S$2.06m (loss narrowed 67% from 1H 2025). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Board Change • Dec 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Non-Executive Director John Teo was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Announcement • Oct 29
iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 6.7 million. iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 6.7 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 67,000,000
Price\Range: SGD 0.1
Discount Per Security: SGD 0.035
Transaction Features: Subsequent Direct Listing Announcement • Oct 28
iX Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of SGD 5 million. iX Biopharma Ltd. has filed a Follow-on Equity Offering in the amount of SGD 5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 50,000,000
Price\Range: SGD 0.1
Discount Per Security: SGD 0.035
Transaction Features: Subsequent Direct Listing Reported Earnings • Oct 10
Full year 2025 earnings released: S$0.012 loss per share (vs S$0.014 loss in FY 2024) Full year 2025 results: S$0.012 loss per share (improved from S$0.014 loss in FY 2024). Revenue: S$7.77m (up 30% from FY 2024). Net loss: S$10.1m (loss narrowed 6.0% from FY 2024). Post-clinical trial products Launched (during full year): 4 Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Announcement • Oct 08
iX Biopharma Ltd., Annual General Meeting, Oct 24, 2025 iX Biopharma Ltd., Annual General Meeting, Oct 24, 2025, at 10:00 Singapore Standard Time. Location: 2 science park drive, ascent main lobby, the metro, singapore 118222, Singapore New Risk • Sep 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Singaporean stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-S$4.0m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 8.7% per year over the past 5 years. Minor Risk Market cap is less than US$100m (S$32.0m market cap, or US$24.8m). Reported Earnings • Aug 31
Full year 2025 earnings released: S$0.012 loss per share (vs S$0.014 loss in FY 2024) Full year 2025 results: S$0.012 loss per share (improved from S$0.014 loss in FY 2024). Revenue: S$7.77m (up 30% from FY 2024). Net loss: S$10.1m (loss narrowed 6.0% from FY 2024). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. New Risk • Aug 26
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-S$5.8m free cash flow). Earnings have declined by 3.6% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported December 2024 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Market cap is less than US$100m (S$17.8m market cap, or US$13.8m). New Risk • May 16
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Singaporean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-S$5.8m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 3.6% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (S$15.1m market cap, or US$11.6m). New Risk • Apr 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-S$5.8m free cash flow). Earnings have declined by 3.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (S$16.9m market cap, or US$12.8m). Reported Earnings • Feb 11
First half 2025 earnings released: S$0.007 loss per share (vs S$0.01 loss in 1H 2024) First half 2025 results: S$0.007 loss per share (improved from S$0.01 loss in 1H 2024). Revenue: S$3.71m (up 39% from 1H 2024). Net loss: S$6.25m (loss narrowed 15% from 1H 2024). Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. New Risk • Feb 08
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -S$5.8m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-S$5.8m free cash flow). Earnings have declined by 3.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (S$19.4m market cap, or US$14.3m). Announcement • Oct 19
iX Biopharma Ltd. Announces Reconstitution of the Board Committees The Board of Directors of iX Biopharma Ltd. announced that with immediate effect, the Audit Committee and the Risk Management Committee of the Company be merged to form the "Audit and Risk Committee". The formation of the Audit and Risk Committee shall streamline the roles and responsibilities of the Board committee members. The Board also refers to its announcement dated 1 October 2024 in relation to the retirement of Ms Angeline Tham as an Independent Director of the Company upon the conclusion of the Annual General Meeting held on 17 October 2024 and wishes to announce that the Board Committees of the Company be reconstituted as follows with immediate effect: Audit and Risk Committee: Teo Woon Keng John-Chairperson, Patrick Donald Davies-Member, Albert Ho Shing Tung-Member. Nominating Committee: Patrick Donald Davies-Chairperson, Teo Woon Keng John-Member, Eddy Lee Yip Hang-Member. Remuneration Committee: Patrick Donald Davies-Chairperson, Albert Ho Shing Tung-Member, Teo Woon Keng John-Member. Reported Earnings • Oct 05
Full year 2024 earnings released: S$0.014 loss per share (vs S$0.013 loss in FY 2023) Full year 2024 results: S$0.014 loss per share (further deteriorated from S$0.013 loss in FY 2023). Revenue: S$5.96m (flat on FY 2023). Net loss: S$10.8m (loss widened 12% from FY 2023). Products in clinical trials Phase I: 1 Phase II: 2 Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings. Announcement • Oct 01
iX Biopharma Ltd., Annual General Meeting, Oct 17, 2024 iX Biopharma Ltd., Annual General Meeting, Oct 17, 2024, at 10:00 Singapore Standard Time. Location: 2 science park drive, ascent main lobby, the metro, singapore 118222, Singapore Reported Earnings • Aug 24
Full year 2024 earnings released: S$0.014 loss per share (vs S$0.013 loss in FY 2023) Full year 2024 results: S$0.014 loss per share (further deteriorated from S$0.013 loss in FY 2023). Revenue: S$5.96m (flat on FY 2023). Net loss: S$10.8m (loss widened 12% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has fallen by 51% per year, which means it is performing significantly worse than earnings. New Risk • Aug 23
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Revenue is less than US$5m (S$6.1m revenue, or US$4.6m). Market cap is less than US$100m (S$23.0m market cap, or US$17.6m). New Risk • Jul 27
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (15% increase in shares outstanding). Revenue is less than US$5m (S$6.1m revenue, or US$4.5m). Market cap is less than US$100m (S$26.5m market cap, or US$19.7m). New Risk • Feb 10
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -S$7.2m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-S$7.2m free cash flow). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (S$6.1m revenue, or US$4.5m). Market cap is less than US$100m (S$32.2m market cap, or US$23.9m). Announcement • Sep 26
iX Biopharma Ltd., Annual General Meeting, Oct 13, 2023 iX Biopharma Ltd., Annual General Meeting, Oct 13, 2023, at 10:00 Singapore Standard Time. Location: 2 Science Park Drive, Ascent Main Lobby, The Metro, Singapore 118222 Singapore Singapore Agenda: To consider the adoption of Directors' Statement and the Audited Financial Statements for the financial year ended 30 June 2023 together with the Auditors' Report thereon; to consider re-election of directors; to consider the payment of Directors' fees of up to SGD 334,000/- for the financial year ending 30 June 2024, to be paid quarterly in arrears; to consider re-appointment of Messrs PricewaterhouseCoopers LLP as Auditors and to authorise the Directors to fix their remuneration; to consider authority to allot and issue shares; to consider authority to allot and issue shares under the iX Employee Share Option Scheme; and to consider authority to allot and issue shares under the iX Performance Share Plan. Reported Earnings • Aug 22
Full year 2023 earnings released: S$0.013 loss per share (vs S$0.006 loss in FY 2022) Full year 2023 results: S$0.013 loss per share (further deteriorated from S$0.006 loss in FY 2022). Revenue: S$5.91m (down 59% from FY 2022). Net loss: S$9.62m (loss widened 109% from FY 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. New Risk • Aug 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Singaporean stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (S$3.7m revenue, or US$2.7m). Market cap is less than US$100m (S$36.0m market cap, or US$26.5m). New Risk • Aug 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (S$3.7m revenue, or US$2.8m). Market cap is less than US$100m (S$34.5m market cap, or US$25.5m). Announcement • Jul 26
iX Biopharma Ltd. announced that it has received SGD 2 million in funding On July 24, 2023, iX Biopharma Ltd. closed the transaction. Announcement • Jul 04
iX Biopharma Ltd. announced that it expects to receive SGD 2 million in funding iX Biopharma Ltd. announced that it entered into a purchase subscription agreement with new investor Lau Ho Ming Peter, to issue convertible bonds for, an aggregate of SGD 2,000,000 principal amount of interest-bearing convertible bonds on July 3, 2023. The securities are convertible into new ordinary shares in the capital of the Company. The securities issued have two years from the subscription Date. The Company will, at least thirty days before the maturity date, give notice to the Subscriber of the maturity date and will make such announcements where applicable. The securities carry 9% per annum payable annually in arrears on 30 June each year. For the avoidance of doubt, all coupons/interests accruing on the bonds will be repaid by the Company in cash, and the Subscriber has no right to convert any coupon/interest into Conversion Shares. Subject to and in compliance with the terms and conditions of the bonds in the subscription agreement and any applicable fiscal or other laws or regulations, the subscriber may exercise the right to convert the Bonds, in whole or in part, into Conversion Shares at any time on or after the date falling 30 days after the issue date of the Bonds up to the date falling 31 days prior to the maturity date. Subject to adjustments as set out in Subscription Agreement, each SGD 1.00 of Bonds can be converted into Conversion Shares at SGD 0.1337 per Conversion Share fractional entitlement to be disregarded. The Conversion Price represents a premium of approximately 47% to SGD 0.0910, being the weighted average price of the Shares for trades done on the Singapore Exchange Securities Trading Limited , for the full market day up to the Subscription Agreement is signed. Subject to the Subscription Agreement, the bonds may be transferred in whole to any third party. For the transfer to be effective, the transferee should not be a person that falls within the categories of persons set out in Rule 812 of the Catalist Rules. However, no bondholder may require the transfer of a bond to be registered during the period of fifteen business days ending on the due date for any payment of any principal on the bonds, or after the certificate in respect of such bonds has been deposited for conversion pursuant to the Subscription Agreement. The bonds constitute direct, unconditional, unsubordinated, and unsecured obligations of the Company, ranking pari passu and ratably without any preference or priority among themselves and will be subordinated to and rank after all the secured and unsecured obligations of the Company. The securities are redeemable at option of the company. The Bonds will not be listed or tradeable on the SGX-ST. The expenses to be incurred in connection with the Proposed bonds Issuance, being professional and administrative fees, are estimated to be approximately SGD 119,000. This includes the fee payable to Crosby Securities in an amount equivalent to SGD 80,000 which will be paid by the Company to Crosby Securities Limited Securities following the completion of the Proposed Convertible Bonds Issuance. Reported Earnings • Feb 12
First half 2023 earnings released: S$0.01 loss per share (vs S$0.005 profit in 1H 2022) First half 2023 results: S$0.01 loss per share (down from S$0.005 profit in 1H 2022). Revenue: S$2.53m (down 81% from 1H 2022). Net loss: S$7.35m (down 301% from profit in 1H 2022). Revenue is forecast to grow 86% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in Asia. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Announcement • Feb 10
iX Biopharma Ltd Successfully Completes Phase 1 Sublingual Dexmedetomidine Clinical Study iX Biopharma Ltd. announced the successful completion of a Phase 1 pharmacokinetic clinical study on the sublingual dexmedetomidine wafer being developed by the Company. The drug is being developed for the treatment of dementia-related agitation, which is an unmet medical need with no drug treatment approved to-date. The clinical study is a 4-way crossover study to evaluate the safety, tolerability and pharmacokinetics of the sublingual dexmedetomidine wafers in 14 healthy volunteers. The study assessed the absolute bioavailability of sublingual dexmedetomidine wafers across the respective dosages of 30mcg, 50mcg, and 100mcg when compared to the intravenous administration of dexmedetomidine, Precedex at 20mcg. The Phase 1 pharmacokinetic clinical study achieved several promising results: High bioavailability: The sublingual wafer showed an impressive 70-80% absolute bioavailability across all dosages tested. Fast onset of action: The sublingual wafer achieved a peak drug concentration in 1.5 hours (Tmax), with drug detectable in plasma as early as 5 minutes post dosing. Dose proportional: The drug exposure was proportional across the dosing range. Safety profile: Sublingual wafers were safe and well tolerated; there were no serious adverse events. Following the success of Phase 1, the Company plans to file an Investigational New Drug application with US Food and Drug Administration to conduct a Phase 2 study on patients with dementia-related agitation. Breakeven Date Change • Nov 16
Forecast to breakeven in 2024 The analyst covering iX Biopharma expects the company to break even for the first time. New forecast suggests the company will make a profit of S$5.34m in 2024. Average annual earnings growth of 86% is required to achieve expected profit on schedule. Announcement • Nov 08
iX Biopharma Ltd. Announces Board and Committee Appointment The Board of Directors of iX Biopharma Ltd. announced the appointment of Mr. Teo Woon Keng John as an Independent Non-Executive Director of the Company and as a member of the Audit Committee, Nominating Committee and Remuneration Committee of the Company with effect from 7 November 2022. The Board considers Mr. Teo Woon Keng John to be independent for the purposes of Catalist Rule 704(7) of the Singapore Exchange Securities Trading Limited ("SGX-ST") Listing Manual Section B: Rules of Catalist. Following the appointment of Mr. Teo Woon Keng John, the Board will be re-constituted as follows: Board of Directors: Eddy Lee Yip Hang: Executive Chairman and Chief Executive Officer; Albert Ho Shing Tung: Non-Independent Non-Executive Director; Patrick Donald Davies: Lead Independent Director; Angeline Tham Xiwen: Independent Non-Executive Director; Teo Woon Keng John: Independent Non-Executive Director. The Nominating Committee and the Board shall deliberate on the reconstitution of the Board Committees of the Company (namely, Audit Committee, Nominating Committee, Remuneration Committee and Risk Management Committee. The Board will make the necessary announcement to update shareholders on the same in due course. Reported Earnings • Aug 24
Full year 2022 earnings released: S$0.006 loss per share (vs S$0.012 loss in FY 2021) Full year 2022 results: S$0.006 loss per share (up from S$0.012 loss in FY 2021). Revenue: S$14.4m (up S$12.6m from FY 2021). Net loss: S$4.60m (loss narrowed 44% from FY 2021). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Jul 22
iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 2.742 million. iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 2.742 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 13,710,000
Price\Range: SGD 0.2
Transaction Features: Subsequent Direct Listing Announcement • Jul 20
iX Biopharma Ltd. Announces Drug Development Updates for Wafermine and Wafesil iX Biopharma Ltd. announced updates on the clinical and drug development programmes for its recently licensed products, Wafermine, a sublingual ketamine wafer, and Wafesil, a sublingual sildenafil wafer. Following iX Biopharma's licensing of Wafermine, its sublingual racemic ketamine wafer, to Seelos Therapeutics Inc. ("Seelos") on 24 November 2021, Seelos has applied to the Food and Drug Administration (FDA) for the transfer of Wafermine's Investigational New Drug Application (IND) from iX Biopharma to itself. A clinical trial to investigate the safety and efficacy of Wafermine for the treatment of patients with Complex Regional Pain Syndrome (CRPS) is in the advanced planning stage. Seelos is currently finalising the study's protocol synopsis and has started exploring feasibility with clinical research organizations and sites. Seelos is targeting final site identification in Third Quarter 2022 and patient enrolment beginning in Fourth Quarter 2022. Announcement • Jul 16
iX Biopharma Ltd. Announces Cessation of Yee Chia Hsing as Director of Corporate Affairs & General Manager of Entity Health Ltd iX Biopharma Ltd. announced that resignation of Mr. Yee Chia Hsing as Director of Corporate Affairs and General Manager of Entity Health Ltd. Reason For Cessation: Mr. Yee Chia Hsing has tendered his resignation with the Company to pursue other career opportunities. To provide continuity, his responsibilities will be taken over by the Company's Chief Commercial Officer, Ms. Eva Tan. Based on its enquiries, the Sponsor is satisfied that, save as disclosed in this announcement, there are no other material reasons for Mr. Yee's cessation as Director of Corporate Affairs and General Manager of Entity Health Ltd. Price Target Changed • Apr 27
Price target decreased to S$0.34 Down from S$0.45, the current price target is provided by 1 analyst. New target price is 81% above last closing price of S$0.18. Stock is down 26% over the past year. The company is forecast to post a net loss per share of S$0.004 next year compared to a net loss per share of S$0.012 last year. Reported Earnings • Feb 14
First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First half 2022 results: EPS: S$0.005 (up from S$0.004 loss in 1H 2021). Revenue: S$13.2m (up S$12.4m from 1H 2021). Net income: S$3.66m (up S$6.48m from 1H 2021). Profit margin: 28% (up from net loss in 1H 2021). Revenue exceeded analyst estimates by 6.4%. Earnings per share (EPS) also surpassed analyst estimates. Over the next year, revenue is expected to shrink by 66% compared to a 20% growth forecast for the industry in Singapore. Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. Announcement • Feb 05
iX Biopharma Ltd. Announces Executive Changes The Board of Directors of iX Biopharma Ltd. announced the resignations of Ms Wang Shin Lin, Adeline and Mr. Lee Wei Hsiung as Secretaries of the company and in their place, Mr. Lai Kuan Loong, Victor and Ms Gwendolin Lee Soo Fern are appointed as Secretaries of the Company with effect from 4 February 2022. Announcement • Jan 30
iX Biopharma Ltd Appoints Angeline Tham as Non-Executive Independent Director, Member of Audit Committee and Remuneration Committee and Chairperson of Nominating Committee, Effective 1 February 2022 The Board of Directors of iX Biopharma Ltd. announced the appointment of Ms. Angeline Tham as a Non-Executive Independent Director of the company with effect from 1 February 2022. Ms Angeline Tham has 17 years of investment strategy, technology, and entrepreneurship experience. She is the founder of Philippines' leading motorcycle ride-hailing application, Angkas, which is known for its social impact and for revolutionising the way motorcycles are perceived in the Philippines. She has also held positions in SoftBank China & India Holdings, a SoftBank affiliated fund, and JP Morgan Chase Singapore, evaluating investment opportunities. She is a graduate of New York University Stern School of Business. Ms Angeline Tham has also been appointed as the member of Audit Committee and Remuneration Committee and chairperson of Nominating Committee. Breakeven Date Change • Nov 24
No longer forecast to breakeven The analyst covering iX Biopharma no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of S$7.57m in 2022. New forecast suggests the company will make a loss of S$2.96m in 2022. Price Target Changed • Oct 20
Price target decreased to S$0.34 Down from S$0.46, the current price target is provided by 1 analyst. New target price is 40% above last closing price of S$0.24. Stock is down 7.7% over the past year. The company is forecast to post a net loss per share of S$0.004 next year compared to a net loss per share of S$0.012 last year. Reported Earnings • Oct 04
Full year 2021 earnings released: S$0.012 loss per share (vs S$0.016 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$1.75m (up 77% from FY 2020). Net loss: S$8.23m (loss narrowed 22% from FY 2020). Products in clinical trials Phase I: 4 Phase II: 1 Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 24
Full year 2021 earnings released: S$0.008 loss per share (vs S$0.016 loss in FY 2020) The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2021 results: Revenue: S$1.75m (up 77% from FY 2020). Net loss: S$8.23m (loss narrowed 22% from FY 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions Derivative • Jul 31
Executive Chairman & CEO exercised options to buy S$2.7m worth of stock. On the 26th of July, Yip Hang Lee exercised options to buy 12m shares at a strike price of around S$0.20, costing a total of S$2.3m. This transaction amounted to 5.7% of their direct individual holding at the time of the trade. Since September 2020, Yip Hang has owned 182.58m shares directly. Company insiders have collectively bought S$2.3m more than they sold, via options and on-market transactions, in the last 12 months. Announcement • Jun 15
iX Biopharma Ltd to Participate in Study with Wafermine for Treatment of Breakthrough Pain in Advanced Cancer Patients iX Biopharma Ltd. announced that it will supply its novel Wafermine sublingual ketamine wafers in a pilot study funded by Chris O'Brien Lifehouse. The study will evaluate the efficacy, acceptability, safety and tolerability of Wafermine administered as a first-line treatment for patients with advanced cancer suffering from moderate to severe pain. The study is a prospective double-blind randomised placebo-controlled repeated cross-over trial and will be carried out at 2 sites, Chris O'Brien Lifehouse cancer centre and Royal Prince Alfred Hospital. It will enrol 32 adult patients with locally advanced or metastatic cancer who experience moderate to severe pain associated with cancer diagnosis requiring ongoing opioid analgesia. The study objectives include the measurement of pain severity, pain impact, side effects and quality of life. The study will be led by Dr. Yi-Ching Lee, Consultant Pain Specialist in Chris O'Brien Lifehouse & Royal Prince Alfred Hospital. A large number of patients in the community suffer from poorly controlled pain associated with advanced cancer. Opioid based medication has been the main treatment for pain, however studies show that more than one third of patients, particularly those with advanced cancer, still experience moderate to severe pain. Ketamine is clinically well established in the management of moderate to severe acute pain, with good evidence for reduction in pain scores, opioid requirements and postoperative nausea and vomiting. Ketamine is currently used as an off-label treatment for breakthrough cancer pain in Australia. However, the current intravenous (IV) route of administration of ketamine limits the drug's broader use in the community. In addition, IV ketamine may result in a severe side effect profile and hence be intolerable to cancer patients. By way of comparison, the benefit of using Wafermine, a sublingual ketamine wafer, is that it is easy to administer and has the potential for a better side effect profile, and therefore it may be better tolerated and more accessible by patients in the community setting. Announcement • Mar 01
iX Biopharma Ltd. Appoints Yee Chia Hsing as Director of Corporate Affairs iX Biopharma Ltd. appointed Yee Chia Hsing as Director of Corporate Affairs, iX Biopharma Ltd. GM of Entity Health. Executive. Promote corporate profiling of the company and Entity Health brand among various stakeholders. He will also assist CEO on various matters as may be needed. Reported Earnings • Feb 11
First half 2021 earnings released: S$0.004 loss per share (vs S$0.009 loss in 1H 2020) First half 2021 results: Net loss: S$2.81m (loss narrowed 51% from 1H 2020). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Announcement • Jan 19
iX Biopharma Ltd. Appoints Ms. Eva Tan as Its New Chief Commercial Officer iX Biopharma Ltd. announce the appointment of Ms. Eva Tan as its new Chief Commercial Officer (CCO) effective immediately. Prior to the appointment, Ms. Tan was formerly iX Biopharma's Director of Corporate and Commercial Strategy, overseeing the commercial, legal and corporate matters pertaining to the Group. Reported Earnings • Oct 04
Full year earnings released - S$0.016 loss per share Over the last 12 months the company has reported total losses of S$10.5m, with losses narrowing by 21% from the prior year. Announcement • Sep 10
iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 10.232999 million. iX Biopharma Ltd. has completed a Follow-on Equity Offering in the amount of SGD 10.232999 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 44,491,299
Price\Range: SGD 0.23
Transaction Features: Subsequent Direct Listing 